首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Treatment of portal vein tumor thrombus of hepatocellular carcinoma with percutaneous laser ablation.
【24h】

Treatment of portal vein tumor thrombus of hepatocellular carcinoma with percutaneous laser ablation.

机译:经皮激光消融治疗肝癌门静脉肿瘤血栓。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUNDS: Portal vein tumor thrombus (PVTT) is a common complication of hepatocellular carcinoma (HCC), and is associated with extremely poor prognosis. PATIENTS AND METHODS: In this retrospective study, we first evaluate the application of percutaneous laser ablation as a treatment for PVTT due to advanced hepatocellular carcinoma. 108 patients (2002.7-2005.12) that have adequate liver function and be in reasonably good general condition were enrolled at Eastern hepatobiliary surgery hospital. The thrombus was ablated via an optic fiber placed in the guide needle with the guiding of ultrasound. In the follow-ups, the serial imaging and laboratory routines were examined and the overall clinical progress was measured at regular intervals until time of death. In the clinical assessment, survival time and factors affecting survival time were analyzed. The changes of laboratory test (alanine transaminase and alpha fetoprotein) and clinical manifestation (ascites and diarrhea) of the PVTT patients before and after laser ablation were observed. RESULTS: Patency of the tumor-occluded portal vein branch is the only factor that affect the survival time, the longer the patency time, the longer the survival time. The long-term survivals of patients in our study are 55.56, 33.58 and 22.38% at 1, 2 and 3 years, respectively. Both laboratory test and clinical presentations were improved. Alphalpha fetoprotein in the positive patients decreased and alanine transaminase in the abnormal patients normalized at 1 month after the treatment. Ascites disappeared in 44.00% patients (11/25), and diarrhea ameliorated in 57.14% (12/21). CONCLUSION: Laser ablation might be a novel and effective treatment for PVTT associated with advanced HCC.
机译:背景:门静脉肿瘤血栓(PVTT)是肝细胞癌(HCC)的常见并发症,并且与预后极差有关。患者与方法:在这项回顾性研究中,我们首先评估经皮激光消融作为晚期肝细胞癌PVTT治疗的应用。东方肝胆外科医院收治了108例肝功能良好且一般情况良好的患者(2002.7-2005.12)。在超声的引导下,通过放置在引导针中的光纤消融血栓。在随访中,检查了连续成像和实验室程序,并定期测量总体临床进展,直至死亡。在临床评估中,分析了生存时间和影响生存时间的因素。观察了激光消融前后PVTT患者实验室检查(丙氨酸转氨酶和甲胎蛋白)的变化以及临床表现(腹水和腹泻)的变化。结果:肿瘤闭塞的门静脉分支的通畅性是影响生存时间的唯一因素,通畅时间越长,生存时间越长。在本研究中,患者在1、2和3年的长期存活率分别为55.56%,33.58%和22.38%。实验室测试和临床表现均得到改善。阳性患者的α-甲胎蛋白下降,而异常患者的丙氨酸转氨酶在治疗后1个月恢复正常。腹水在44.00%的患者中消失(11/25),腹泻减轻了57.14%(12/21)。结论:激光消融可能是一种治疗晚期肝癌的PVTT的新型有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号